Project

Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: A noninferiority phase III trial (SAKK 96/12, REDUSE)

Ongoing - recruitment closed · 2014 until 2026

Fischer Stefanie, Sakic Miranda, Quinter Janine